Current views on the etiopathogenesis of thyroid ophthalmopathy

Central-European Journal of Immunology

Volumn 29, Issue 3-4, 2004, Pages 94-99

  Ła̧cka, Katarzyna ^a   Szarzyńska, Joanna ^b   Ła̧cki, Jan K ^c  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^b City Hospital of Poznan   (Poland)

^c INSTITUTE OF RHEUMATOLOGY   (Poland)

Author keywords

Cytokines; Gene polymorphism; Inflammatory process; Thyroid associated ophthalmopathy

Indexed keywords

CYTOKINE; INTERFERON; TUMOR NECROSIS FACTOR ALPHA;

CLINICAL FEATURE; DISEASE COURSE; DNA POLYMORPHISM; ENDOCRINE OPHTHALMOPATHY; ENVIRONMENTAL FACTOR; FIBROBLAST; HEREDITY; HUMAN; INFLAMMATION; MEDICAL RESEARCH; PATHOGENESIS; PREVALENCE; REVIEW; THYROID CELL;

EID: 33644505771     PISSN: 14263912     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (52)

1. Bartley GB, Fatourechi V, Kadrmas EF, et al. (1995): The incidence of Graves' ophthalmopathy in Olmsted County, Minnesota. Am J Ophthalmol 120: 511-517.
2. Perros P, Crombie AL, Matthews JNS, Kendall-Taylor P (1993): Age and gender influence the severity of thyroid-associated ophthalmopathy: a study of 101 patients attending a combined thyroid-eye clinic. Clin Endocrinol (Oxf) 38 (4): 367-372.
3. Werner SC (1969): Classification of the eye changes of Grave's disease. J Clin Endocrinol Metab 29: 982-984.
4. Werner SC (1977): Modification of the classification of the eye changes of Graves' disease: recommendations of the Ad Hoc Committee of the American Thyroid Association. J Clin Endocrinol Metab 44: 203-204.
5. Classification of eye changes of Graves' disease (1992): Thyroid 2 (3): 235-236.
6. Hallin ES, Feldon SE (1988): Graves' ophthalmopathy: I. Simple CT estimates of extraocular muscle volume. Br J Ophthalmol 72 (9): 674-677.
7. Yamamoto K, Itoh K, Yoshida S, et al. (1979): A quantitative analysis of orbital soft tissue in Graves' disease based on B-mode ultrasonography. Endocrinol Jpn 26 (2): 255-261.
8. Wing SD, Hunsaker JN, Anderson RE, et al. (1979): Direct sagittal computed tomography in Graves' ophthalmopathy. J Comput Assist Tomogr 3 (6): 820-824.
9. Tomer Y, Davies TF (1993): Infection, thyroid disease, and autoimmunity. Endocr Rev 14 (1): 107-120.
10. Corapcioglu D, Tonyukuk V, Kiyan M, Yilmaz AE, Emral R, Kamel N, Erdogan G (2002): Relationship between thyroid autoimmunity and Yersinia enterocolitica antibodies. Thyroid 12 (7): 613-617.
11. Wenzel BE, Peters A, Zubaschev I (1996): Bacterial virulence antigens and the pathogenesis of autoimmune thyroid diseases (AITD). Exp Clin Endocrinol Diabetes 104 Suppl 4: 75-78.
12. Vestergaard P (2002): Smoking and thyroid disorders - a meta-analysis. Eur J Endocrinol 146(2): 153-161.
13. Bartalena L, Marcocci C, Tanda ML, et al. (1998): Cigarette smoking and treatment outcomes in Graves ophthalmopathy. Ann Intern Med 129 (8): 632-635.
14. Bartalena L, Martino E, Marcocci C, et al. (1989): More on smoking habits and Graves' ophthalmopathy. J Endocrinol Invest 12 (10): 733-737.
15. Mann K, Gieseler R, Hormann R (1999): Aetiopathogenese des Morbus Basedow. Z Arztl Fortbild Qualitatssich 93 (Suppl 1): 29-34.
16. Heufelder AE (2000): Pathogenesis of ophthalmopathy in autoimmune thyroid disease. Rev Endocr Metab Disord 1 (1-2): 87-95.
17. Bednarczuk T, Kiljanski J, Mrowiec T, et al. (1998): T cell interactions with extracellular matrix proteins in patients with thyroid-associated ophthalmopathy. Autoimmunity 27 (4): 221-230.
18. Hiromatsu Y, Kaku H, Miyake I, et al. (2002): Role of cytokines in the pathogenesis of thyroid-associated ophthalmopathy. Thyroid 12 (3): 217-221.
19. Rasmussen AK (2000): Cytokine actions on the thyroid gland. Dan Med Bull 47 (2): 94-114.
20. Wakelkamp IM, Gerding MN, Van Der Meer JW, et al. (2000): Both Th1- and Th2-derived cytokines in serum are elevated in Graves' ophthalmopathy. Clin Exp Immunol 121 (3): 453-457.
21. Ajjan RA, Watson PF, Weetman AP (1996): Cytokines and thyroid function. Adv Neuroimmunol 6 (4): 359-386.
22. Diez JJ, Hernanz A, Ma S, et al. (2002): Serum concentrations of tumour necrosis factor-alpha (TNF-alpha) and soluble TNF-alpha receptor p55 in patients with hypothyroidism and hyperthyroidism before and after normalization of thyroid function. Clin Endocrinol (Oxf) 57 (4): 515-521.
23. Valyasevi RW, Jyonouchi SC, Dutton CM, et al. (2001): Effect of tumor necrosis factor-alpha, interferon-gamma, and transforming growth factor-beta on adipogenesis and expression of thyrotropin receptor in human orbital preadipocyte fibroblasts. J Clin Endocrinol Metab 86 (2): 903-908.
24. Ban Y, Taniyama M, Tozaki T, et al. (2001): SEL1L microsatellite polymorphism in Japanese patients with autoimmune thyroid diseases. Thyroid 11 (4): 335-338.
25. Takiyama Y, Miyokawa N, Tokusashi Y, et al. (2002): Thyroid-stimulating hormone induces interleukin-18 gene expression in FRTL-5 cells: immunohistochemical detection of interleukin-18 in autoimmune thyroid disease. Thyroid 12 (11): 935-943.
26. de la Vega JR, Vilaplana JC, Biro A, et al. (1998): IL-10 expression in thyroid glands: protective or harmful role against thyroid autoimmunity? Clin Exp Immunol 113 (1): 126-135.
27. Ajjan RA, Watson PF, Weetman AP (1997): Detection of IL-12, IL-13, and IL-15 messenger ribonucleic acid in the thyroid of patients with autoimmune thyroid disease. J Clin Endocrinol Metab 82 (2): 666-669.
28. Molnar I, Balazs C (1997): High circulating IL-6 level in Graves' ophthalmopathy. Autoimmunity 25 (2): 91-96.
29. Paschke R, Schuppert F, Taton M, Velu T (1994): Intrathyroidal cytokine gene expression profiles in autoimmune thyroiditis. J Endocrinol 141 (2): 309-315.
30. Yoshikawa N, Morita T, Arreaza G, et al. (1995): The effect of interleukin-2 on suppressor T lymphocytes in autoimmune thyroid disease. Clin Invest Med 18 (2): 91-98.
31. Watson PF, Pickerill AP, Davies R, Weetman AP (1995): Semi-quantitative analysis of interleukin-1 alpha, interleukin-6 and interleukin-8 mRNA expression by human thyrocytes. J Mol Endocrinol 15(1): 11-21.
32. Watson PF, Pickerill AP, Davies R, Weetman AP (1994): Analysis of cytokine gene expression in Graves' disease and multinodular goiter. J Clin Endocrinol Metab 79 (2): 355-360.
33. Pappa A, Calder V, Fells P, Lightman S (1997): Adhesion molecule expression in vivo on extraocular muscles (EOM) in thyroid-associated ophthalmopathy (TAO). Clin Exp Immunol 108 (2): 309-313.
34. Kulig G, Pilarska K, Kulig J, et al. (2002): Usefulness of soluble ICAM-1 measurements for the evaluation of the disease activity and efficiency of therapy in patients with infiltrative Graves' ophthalmopathy. Pol Arch Med Wewn 108 (6): 1161-1169.
35. Heufelder AE, Bahn RS (1993): Elevated expression in situ of selectin and immunoglobulin superfamily type adhesion molecules in retroocular connective tissues from patients with Graves' ophthalmopathy. Clin Exp Immunol 91 (3): 381-389.
36. Villanueva R, Inzerillo AM, Tomer Y, et al. (2000): Limited genetic susceptibility to severe Graves' ophthalmopathy: no role for CTLA-4 but evidence for an environmental etiology. Thyroid 10 (9): 791-798.
37. Ban Y, Davies TF, Greenberg DA, et al. (2002): The influence of human leucocyte antigen (HLA) genes on autoimmune thyroid disease (AITD): results of studies in HLA-DR3 positive AITD families. Clin Endocrinol (Oxf) 57 (1): 81-88.
38. Hunt PJ, Marshall SE, Weetman AP, et al. (2000): Cytokine gene polymorphisms in autoimmune thyroid disease. J Clin Endocrinol Metab 85 (5): 1984-1988.
39. Chistyakov DA, Savost'anov KV, Turakulov RI, et al. (2000): Complex association analysis of Graves' disease using a set of polymorphic markers. Mol Genet Metab 70 (3): 214-218.
40. Kouki T, Sawai Y, Gardine CA, et al. (2000): CTLA-4 gene polymorphism at position 49 in exon 1 reduces the inhibitory function of CTLA-4 and contributes to the pathogenesis of Graves' disease. J Immunol 165 (11): 6606-6611.
41. Vaidya B, Imrie H, Perros P, et al. (1999): The cytotoxic T lymphocyte antigen-4 is a major Graves' disease locus. Hum Mol Genet 8 (7): 1195-1199.
42. Vaidya B, Imrie H, Perros P, et al. (1999): Cytotoxic T lymphocyte antigen-4 (CTLA-4) gene polymorphism confers susceptibility to thyroid associated orbitopathy. Lancet 354 (9180): 743-744.
43. Kotsa K, Watson PF, Weetman AP (1997): A CTLA-4 gene polymorphism is associated with both Graves disease and autoimmune hypothyroidism. Clin Endocrinol (Oxf) 46 (5): 551-554.
44. Yanagawa T, Taniyama M, Enomoto S, et al. (1997): CTLA4 gene polymorphism confers susceptibility to Graves' disease in Japanese. Thyroid 7 (6): 843-846.
45. Badenhoop K, Donner H, Braun J, et al. (1996): Genetic markers in diagnosis and prediction of relapse in Graves' disease. Exp Clin Endocrinol Diabetes 104 (Suppl 4): 98-100.
46. Yanagawa T, Hidaka Y, Guimaraes V, et al. (1995): CTLA-4 gene polymorphism associated with Graves' disease in a Caucasian population. J Clin Endocrinol Metab 80 (1): 41-45.
47. Zaletel K, Krhin B, Gaberscek S, Pirnat E, Hojker S (2002): The influence of the exon 1 polymorphism of the cytotoxic T lymphocyte antigen 4 gene on thyroid antibody production in patients with newly diagnosed Graves' disease. Thyroid 12 (5): 373-376.
48. Kouki T, Gardine CA, Yanagawa T, Degroot LJ (2002): Relation of three polymorphisms of the CTLA-4 gene in patients with Graves' disease. J Endocrinol Invest 25 (3): 208-213.
49. Mochizuki M, Amemiya S, Kobayashi K, et al. (2003): Association of the CTLA-4 gene 49 A/G polymorphism with type 1 diabetes and autoimmune thyroid disease in Japanese children. Diabetes Care 26 (3): 843-847.
50. Einarsdottir E, Soderstrom I, Lofgren-Burstrom A, et al. (2003): The CTLA4 region as a general autoimmunity factor: an extended pedigree provides evidence for synergy with the HLA locus in the etiology of type 1 diabetes mellitus, Hashimoto's thyroiditis and Graves' disease. Eur J Hum Genet 11 (1): 81-84.
51. Akamizu T, Sale MM, Rich SS, et al. (2000): Association of autoimmune thyroid disease with microsatellite markers for the thyrotropin receptor gene and CTLA-4 in Japanese patients. Thyroid 10 (10): 851-858.
52. Kamizono S, Hiromatsu Y, Seki N, et al. (2000): A polymorphism of the 5' flanking region of tumour necrosis factor alpha gene is associated with thyroid-associated ophthalmopathy in Japanese. Clin Endocrinol (Oxf) 52 (6): 759-764.